NCT02306694View on ClinicalTrials.gov

Prospective Biomarkers of Bone Metabolism in Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 16, 2018

Study Completion Date

April 16, 2018

Conditions
HemophiliaBone Disease
Interventions
DRUG

Advate

Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT02306694 - Prospective Biomarkers of Bone Metabolism in Hemophilia A | Biotech Hunter | Biotech Hunter